Therapeutic Strategies For Alzheimer's Solution | cannabisMD

Therapeutic Strategies in the Search of Alzheimer’s Solution

Alzheimers Solution

There are thousands upon thousands of scientific articles on Alzheimer’s Disease (AD). Adequate therapy for Alzheimer’s Disease (AD) is lacking and this is why there is a significant amount of growing reviews and papers on the efforts of finding a treatment/cure for Alzheimer’s disease. to the continuously growing amount of papers and reviews, reflecting the extraordinary efforts made by scientists in this field. Alzheimer’s Disease is the most common cause of dementia (dementia is just an umbrella term). So far, there is no prevention therapy or cure for AD, which is why so many experts are putting in a lot of effort to help find a potential treatment.

This review offers a view of the current state of knowledge about Alzheimer’s Disease which includes more relevant findings and processes that take part in the disease; it also shows more relevant past, present and future research on therapeutic drugs taking into account the new paradigm “Multi-Target-Directed Ligands” (MTDLs).

Here is the full scientific article if you wish to download it.

Natural Origin MTDL – Cannabinoids in AD Therapy

Cannabinoids from the cannabis plant have been taking into consideration as a potential treatment for Alzheimer’s Disease. The study states that there is a connection between Alzheimer’s disease and the endocannabinoid system (ECS). This is something that has been consistently reported.

The study suggests that cannabis has anti-aggression, anti-glutamatergic effects, antioxidant activity, and anti-neuroinflammation.

The study says

“Targeting the AD appears to be very elusive, although some general pathways –not exclusive to AD- are recognized in different pathogenic cascades, each of them has conducted various “hypothesis” of AD. Researchers are following different approaches to find the optimal molecules. Strategies that according to Grill and Cummings can be classified into two groups, depending on where is the focus for the drug targets is that is, symptomatic therapies, and disease-modifying therapies”

Jonathan Neilly
Jonathan Neilly
Jonathan Neilly is registered with the British Psychological Society, breaking the taboo on mental health issues is one of the driving forces in his life. His background in biomedicine gives him additional understanding of the factors that work together to influence the human condition.

Leave a Reply

Your email address will not be published. Required fields are marked *